A mechanistic study on reduced toxicity of irinotecan by coadministered thalidomide, a tumor necrosis factor-α inhibitor

Journal of Pharmacology and Experimental Therapeutics

Volumn 319, Issue 1, 2006, Pages 82-104

  Yang, Xiao Xia ^a   Hu, Ze Ping ^a   Xu, An Long ^c   Duan, Wei ^b   Zhu, Yi Zhun ^b   Huang, Min ^c   Sheu, Fwu Shan ^a   Zhang, Qiang ^d   Bian, Jin Song ^b   Chan, Eli ^a   Li, Xiaotian ^e   Wang, Jian Cheng ^d   Zhou, Shu Feng ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c SUN YAT SEN UNIVERSITY   (China)

^d PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^e FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; 7 ETHYL 10 HYDROXYCAMPTOTHECIN GLUCURONIDE; CYTOKINE; GAMMA INTERFERON; GLUTAMIC ACID DERIVATIVE; GLYCOPROTEIN P; INTERLEUKIN 1; INTERLEUKIN 6; IRINOTECAN; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; NIFEDIPINE; PROBENECID; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; VERAPAMIL; VERLUKAST;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BONE MARROW SUPPRESSION; CELL STRAIN; CELL STRAIN CACO 2; CONTROLLED STUDY; DIARRHEA; DRUG TRANSPORT; GASTROINTESTINAL TOXICITY; HISTOLOGY; HUMAN; HUMAN CELL; HYDROLYSIS; INTESTINE EPITHELIUM; INTESTINE INJURY; LIVER CELL; LIVER MICROSOME; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TOXICITY; TRANSPORT KINETICS; WEIGHT REDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BILE; BLOOD PROTEINS; BONE MARROW; CACO-2 CELLS; CAMPTOTHECIN; DIARRHEA; HEPATOCYTES; HUMANS; INTESTINES; MALE; MEMBRANE TRANSPORT PROTEINS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; P-GLYCOPROTEIN; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; THALIDOMIDE; TUMOR NECROSIS FACTOR-ALPHA; WEIGHT LOSS;

EID: 33749028208     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.106.103606     Document Type: Article

References (35)

1. Ando Y, Fuse E, and Figg WD (2002) Thalidomide metabolism by the CYP2C subfamily. Clin Cancer Res 8:1964-1973.
2. Benson AB 3rd, Ajani JA, Catalano RB, Engelking C, Kornblau SM, Martenson JA Jr, McCallum R, Mitchell EP, O'Dorisio TM, Vokes EE, et al. (2004) Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol 22:2918-2926.
3. Catley L, Tai YT, Chauhan D, and Anderson KC (2005) Perspectives for combination therapy to overcome drug-resistant multiple myeloma. Drug Resist Updat 8:205-218.
4. Charasson V, Haaz MC, and Robert J (2002) Determination of drug interactions occurring with the metabolic pathways of irinotecan. Drug Metab Dispos 30:731-733.
5. Chu XY, Kato Y, Ueda K, Suzuki H, Niinuma K, Tyson CA, Weizer V, Dabbs JE, Froehlich R, Green CE, et al. (1998) Biliary excretion mechanism of CPT-11 and its metabolites in humans: involvement of primary active transporters. Cancer Res 58:5137-5143.
6. Chu XY, Suzuki H, Ueda K, Kato Y, Akiyama S, and Sugiyama Y (1999) Active efflux of CPT-11 and its metabolites in human KB-derived cell lines. J Pharmacol Exp Ther 288:735-741.
7. Fang HL, Abdolalipour M, Duanmu Z, Smigelski JR, Weckle A, Kocarek TA, and Runge-Morris M (2005) Regulation of glucocorticoid-inducible hydroxysteroid sulfotransferase (SULT2A-40/41) gene transcription in primary cultured rat hepatocytes: role of CCAAT/enhancer-binding protein liver-enriched transcription factors. Drug Metab Dispos 33:147-156.
8. Franks ME, Macpherson GR, and Figg WD (2004) Thalidomide. Lancet 363:1802-1811.
9. Govindarajan R, Heaton KM, Broadwater R, Zeitlin A, Lang NP, and Hauer-Jensen M (2000) Effect of thalidomide on gastrointestinal toxic effects of irinotecan. Lancet 356:566-567.
10. Gupta E, Lestingi TM, Mick R, Ramirez J, Vokes EE, and Ratain MJ (1994) Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res 54:3723-3725.
11. Gupta E, Luo F, Lallo A, Ramanathan S, Vyas V, Rubin E, and Sinko P (2000) The intestinal absorption of camptothecin, a highly lipophilic drug, across Caco-2 cells is mediated by active transporter (s). Anticancer Res 20:1013-1016.
12. Haaz MC, Rivory L, Riche C, Vernillet L, and Robert J (1998) Metabolism of irinotecan (CPT-11) by human hepatic microsomes: participation of cytochrome P-450 3A and drug interactions. Cancer Res 58:468-472.
13. Hu Z, Yang X, Ho PC, Chan E, Chan SY, Xu C, Li X, Zhu YZ, Duan W, Chen X, et al. (2005) St. John's wort modulates the toxicities and pharmacokinetics of CPT-11 (irinotecan) in rats. Pharm Res (NY) 22:902-914.
14. Kestell P, Zhao L, Ching L-M, Baguley BC, and Paxton JW (2000) Modulation of the plasma pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid by thalidomide in mice. Cancer Chemother Pharmacol 46:135-141.
15. Kurita A, Kado S, Kaneda N, Onoue M, Hashimoto S, and Yokokura T (2003) Alleviation of side effects induced by irinotecan hydrochloride (CPT-11) in rats by intravenous infusion. Cancer Chemother Pharmacol 52:349-360.
16. Li J, Zhou S, Huynh H, and Chan E (2005) Significant intestinal excretion, one source of variability in pharmacokinetics of COL-3, a chemically modified tetracycline. Pharm Res (NY) 22:397-404.
17. Marini M, Bamias G, Rivera-Nieves J, Moskaluk CA, Hoang SB, Ross WG, Pizarro TT, and Cominelli F (2003) TNF-alpha neutralization ameliorates the severity of murine Crohn's-like ileitis by abrogation of intestinal epithelial cell apoptosis. Proc Natl Acad Sci USA 100:8366-8371.
18. Mathijssen RH, van Alphen RJ, Verweij J, Loos WJ, Nooter K, Stoter G, and Sparreboom A (2001) Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 7:2182-2194.
19. Miampamba M, Parr EJ, McCafferty DM, Wallace JL, and Sharkey KA (1998) Effect of intracolonic benzalkonium chloride on trinitrobenzene sulphonic acid-induced colitis in the rat. Aliment Pharmacol Ther 12:219-228.
20. Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, and Kaplan G (1993) Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med 177:1675-1680.
21. Pizzolato JF and Saltz LB (2003) The camptothecins. Lancet 361:2235-2242.
22. Rothenberg ML, Eckardt JR, Kuhn JG, Burris HA 3rd, Nelson J, Hilsenbeck SG, Rodriguez GI, Thurman AM, Smith LS, Eckhardt SG, et al. (1996) Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol 14:1128-1135.
23. Sonis ST (2004) The pathobiology of mucositis. Nat Rev Cancer 4:277-284.
24. Thompson CB (1995) Apoptosis in the pathogenesis and treatment of disease. Science (Wash DC) 267:1456-1462.
25. Tian Q, Zhang J, Tan TM, Chan E, Duan W, Chan SY, Boelsterli UA, Ho PC, Yang H, Bian JS, et al. (2005) Human multidrug resistance associated protein 4 confers resistance to camptothecins. Pharm Res (NY) 22:1837-1853.
26. Trifan OC, Durham WF, Salazar VS, Horton J, Levine BD, Zweifel BS, Davis TW, and Masferrer JL (2002) Cyclooxygenase-2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side effect of CPT-11. Cancer Res 62: 5778-5784.
27. Wu B, Fujise T, Iwakiri R, Ootani A, Amemori S, Tsunada S, Toda S, and Fujimoto K (2004) Venous congestion induces mucosal apoptosis via tumor necrosis factor-alpha-mediated cell death in the rat small intestine. J Gastroenterol 39:1056-1062.
28. Yamaoka K, Nakagawa T, and Uno T (1978) Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm 6:165-167.
29. Yang XX, Hu ZP, Chan SY, Goh BC, Chan E, Duan W, and Zhou SF (2005a) Novel agents that potentially inhibit CPT-11-induced diarrhea. Curr Med Chem 12:763-781.
30. Yang X, Hu Z, Chan SY, Ho PC, Chan E, Duan W, Goh BC, and Zhou S (2005b) Determination of thalidomide by high performance liquid chromatography: Plasma pharmacokinetic studies in the rat. J Pharm Biomed Anal 39:299-304.
31. Yokoi T, Narita M, Nagai E, Hagiwara H, Aburada M, and Kamataki T (1995) Inhibition of UDP-glucuronosyltransferase by aglycons of natural glucuronides in kampo medicines using SN-38 as a substrate. Jpn J Cancer Res 86:985-989.
32. Zhang J, Huang M, Guan S, Bi HC, Pan Y, Duan W, Chan SY, Chen X, Hong YH, Bian JS, et al. (2006) A mechanistic study of the intestinal absorption of cryptotanshinone, the major active constituent of Salvia miltiorrhiza. J Pharmacol Exp Ther 317:1285-1294.
33. Zhao J, Huang L, Belmar N, Buelow R, and Fong T (2004) Oral RDP58 allows CPT-11 dose intensification for enhanced tumor response by decreasing gastrointestinal toxicity. Clin Cancer Res 10:2851-2859.
34. Zhou S, Paxton JW, Kestell P, and Tingle MD (2001a) Reversible binding of the novel anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid to plasma proteins and its distribution into blood cells in various species. J Pharm Pharmacol 53:463-471.
35. Zhou S, Paxton JW, Kestell P, Tingle MD, and Ching LM (2001b) In vitro and in vivo kinetic interactions of the antitumour agent 5,6-dimethylxanthenone- 4-acetic acid with thalidomide and diclofenac. Cancer Chemother Pharmacol 47:319-326.